TY - JOUR
T1 - Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation
T2 - How much progress has been made?
AU - Horan, John T.
AU - Logan, Brent R.
AU - Agovi-Johnson, Manza A.
AU - Lazarus, Hillard M.
AU - Bacigalupo, Andrea A.
AU - Ballen, Karen K.
AU - Bredeson, Christopher N.
AU - Carabasi, Matthew H.
AU - Gupta, Vikas
AU - Hale, Gregory A.
AU - Khoury, Hanna Jean
AU - Juckett, Mark B.
AU - Litzow, Mark R.
AU - Martino, Rodrigo
AU - McCarthy, Philip L.
AU - Smith, Franklin O.
AU - Rizzo, J. Douglas
AU - Pasquini, Marcelo C.
PY - 2011/3/1
Y1 - 2011/3/1
N2 - Purpose: Transplantation-related mortality (TRM) is a major barrier to the success of allogeneic hematopoietic cell transplantation (HCT). Patients and Methods: We assessed changes in the incidence of TRM and overall survival from 1985 through 2004 in 5,972 patients younger than age 50 years who received myeloablative conditioning and HCT for acute myeloid leukemia (AML) in first complete remission (CR1) or second complete remission (CR2). Results: Among HLA-matched sibling donor transplantation recipients, the relative risks (RRs) for TRM were 0.5 and 0.3 for 2000 to 2004 compared with those for 1985 to 1989 in patients in CR1 and CR2, respectively (P < .001). The RRs for all causes of mortality in the latter period were 0.73 (P < .001) and 0.60 (P < .005) for the CR1 and CR2 groups, respectively. Among unrelated donor transplantation recipients, the RRs for TRM were 0.73 (P = .095) and 0.58 (P < .001) for 2000 to 2004 compared with those in 1990 to 1994 in the CR1 and CR2 groups, respectively. Reductions in mortality were observed in the CR2 group (RR, 0.74; P = .03) but not in the CR1 group. Conclusion: Our results suggest that innovations in transplantation care since the 1980s and 1990s have reduced the risk of TRM in patients undergoing allogeneic HCT for AML and that this reduction has been accompanied by improvements in overall survival.
AB - Purpose: Transplantation-related mortality (TRM) is a major barrier to the success of allogeneic hematopoietic cell transplantation (HCT). Patients and Methods: We assessed changes in the incidence of TRM and overall survival from 1985 through 2004 in 5,972 patients younger than age 50 years who received myeloablative conditioning and HCT for acute myeloid leukemia (AML) in first complete remission (CR1) or second complete remission (CR2). Results: Among HLA-matched sibling donor transplantation recipients, the relative risks (RRs) for TRM were 0.5 and 0.3 for 2000 to 2004 compared with those for 1985 to 1989 in patients in CR1 and CR2, respectively (P < .001). The RRs for all causes of mortality in the latter period were 0.73 (P < .001) and 0.60 (P < .005) for the CR1 and CR2 groups, respectively. Among unrelated donor transplantation recipients, the RRs for TRM were 0.73 (P = .095) and 0.58 (P < .001) for 2000 to 2004 compared with those in 1990 to 1994 in the CR1 and CR2 groups, respectively. Reductions in mortality were observed in the CR2 group (RR, 0.74; P = .03) but not in the CR1 group. Conclusion: Our results suggest that innovations in transplantation care since the 1980s and 1990s have reduced the risk of TRM in patients undergoing allogeneic HCT for AML and that this reduction has been accompanied by improvements in overall survival.
UR - http://www.scopus.com/inward/record.url?scp=79952356420&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952356420&partnerID=8YFLogxK
U2 - 10.1200/JCO.2010.32.5001
DO - 10.1200/JCO.2010.32.5001
M3 - Article
C2 - 21220593
AN - SCOPUS:79952356420
SN - 0732-183X
VL - 29
SP - 805
EP - 813
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 7
ER -
